logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Synthetic peptides hit three targets simultaneously in recurrent glioblastoma

Updated phase II data for the novel immunotherapeutic (SL-701) show “preliminarily promising survival curve” with good tolerability